Kymera Therapeutics (KYMR) Cash & Equivalents (2019 - 2026)

Kymera Therapeutics (KYMR) has 8 years of Cash & Equivalents data on file, last reported at $144.1 million in Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $144.1 million, up 60.16% year-over-year; the trailing twelve-month figure through Mar 2026 was $144.1 million (up 60.16% YoY), and the FY2025 annual result was $357.0 million, up 196.88% from the prior year.
• Cash & Equivalents declined to $144.1 million in Q1 2026 per KYMR's latest filing, from $357.0 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $357.0 million in Q4 2025 and troughed at $33.7 million in Q1 2022.
• A 5-year average of $121.2 million and a median of $93.5 million in 2024 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2023 and 2025: Cash & Equivalents slumped 47.93% in 2023, then jumped 396.68% in 2025.
• A 5-year view of Cash & Equivalents shows it stood at $68.4 million in 2022, then surged by 60.78% to $110.0 million in 2023, then climbed by 9.36% to $120.3 million in 2024, then soared by 196.88% to $357.0 million in 2025, then sank by 59.64% to $144.1 million in 2026.
• Business Quant data shows KYMR's Cash & Equivalents at $144.1 million in Q1 2026, $357.0 million in Q4 2025, and $112.9 million in Q3 2025.